Industry Trend Analysis - Revenues Of EUR1.3bn Anticipated For Krka In FY18 - APR 2018


BMI View: Krka's more traditional markets of East and Central Europe remain key to the firm's revenues, and alongside sales from West Europe, make up the dominant part of Krka's revenue breakdown. With prescription pharmaceutical sales surpassing the EUR1bn mark for the first time in Krka's history, Krka's outlook for FY18 is positive, with revenues of EUR1.3bn anticipated.

For FY17, ended December 31 2017, Krka Group reported revenues worth EUR1,266.4mn (USD1,430.4mn), up by 7.8% over the EUR1,174.4mn reported a year earlier. Group net profit saw a substantial turnaround, rising by 40.7%, from EUR108.5mn in FY16 to EUR152.6mn (USD172.3mn). Krka's revenues are at their highest level for the last six years and have broken the EUR1.2bn mark for the first time since FY13, when the firm recorded Group revenues worth EUR1,200.8mn. The rise in net profit will be particularly welcome; net profit fell between FY13 and FY16, from EUR172.8mn to EUR108.5mn. These top-line results fit with Krka's expectations; in FY16, the company anticipated sales for FY17 would be worth around EUR1,220mn, and net profit would exceed that reported for FY16. For FY18, Krka Group revenues are planned to reach EUR1.3bn, with profit of EUR153mn.

East Europe Remains The Largest Market

Krka's Revenues Bounce Back
Krka's Top-Line Annual Results (EUR000s)
Source: Krka, BMI

This article is part of our Emerging Europe coverage. To access this article subscribe now or sign up for free trial